596 related articles for article (PubMed ID: 2465302)
1. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
3. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous determination of testosterone, dihydrotestosterone and 5 alpha-androstan-3 alpha,-17 beta-diol by isotopic dilution mass spectrometry in plasma and prostatic tissue of patients affected by benign prostatic hyperplasia. Effects of 3-month treatment with a GnRH analog.
Salerno R; Moneti G; Forti G; Magini A; Natali A; Saltutti C; Di Cello V; Costantini A; Serio M
J Androl; 1988; 9(4):234-40. PubMed ID: 2460425
[TBL] [Abstract][Full Text] [Related]
5. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
van der Sluis TM; Meuleman EJ; van Moorselaar RJ; Bui HN; Blankenstein MA; Heijboer AC; Vis AN
BJU Int; 2012 Jan; 109(2):183-8. PubMed ID: 21992404
[TBL] [Abstract][Full Text] [Related]
6. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V
J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
[TBL] [Abstract][Full Text] [Related]
7. Decreased urinary 5 alpha-androstane-3 alpha,17 beta-diol glucuronide excretion in patients with benign prostatic hyperplasia.
Wright F; Poizat R; Bongini M; Bozzolan F; Doukani A; Mauvais-Jarvis P
J Clin Endocrinol Metab; 1985 Feb; 60(2):294-8. PubMed ID: 2578133
[TBL] [Abstract][Full Text] [Related]
8. [Endogenous androgen levels of human prostatic tissues].
Morioka M; Takeda K; Mitsuhata N; Ohashi T; Ohmori H; Saito T; Kanbegawa A
Nihon Naibunpi Gakkai Zasshi; 1982 Jul; 58(7):876-85. PubMed ID: 6182032
[TBL] [Abstract][Full Text] [Related]
9. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
10. Determination of testosterone and its tissue metabolites (DHT and 3 alpha-diol) in human plasma and prostatic tissue by isotopic dilution mass spectrometry.
Moneti G; Giovannini MG; Guarna A; Forti G; Salerno R; Magini A; Serio M
J Steroid Biochem; 1987; 27(1-3):53-9. PubMed ID: 2447389
[TBL] [Abstract][Full Text] [Related]
11. Effect of megestrol acetate (Megace) on steroid metabolism and steroid-protein binding in the human prostate.
Geller J; Albert J; Geller S; Lopez D; Cantor T; Yen S
J Clin Endocrinol Metab; 1976 Nov; 43(5):1000-8. PubMed ID: 62759
[TBL] [Abstract][Full Text] [Related]
12. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of follicle stimulating hormone, luteinizing hormone, prolactin, testosterone, 5 alpha-dihydrotestosterone, 5 alpha-androstane-3 alpha, 17 beta-diol, 5 alpha-androstane-3 beta, 17 beta-diol, and 17 beta-estradiol from male beagles with spontaneous or induced benign prostatic hyperplasia.
Cochran RC; Ewing LL; Niswender GD
Invest Urol; 1981 Nov; 19(3):142-7. PubMed ID: 6170603
[TBL] [Abstract][Full Text] [Related]
14. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
van der Sluis TM; Vis AN; van Moorselaar RJ; Bui HN; Blankenstein MA; Meuleman EJ; Heijboer AC
BJU Int; 2012 Jan; 109(2):176-82. PubMed ID: 21992222
[TBL] [Abstract][Full Text] [Related]
15. Relationships between oestradiol-17 beta, testosterone, dihydrotestosterone and 5 alpha-androstane-3 alpha, 27 beta-diol in human benign hypertrophy and carcinoma of the prostate.
Ghanadian R; Puah CM
J Endocrinol; 1981 Feb; 88(2):255-62. PubMed ID: 6162906
[TBL] [Abstract][Full Text] [Related]
16. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
17. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
18. Dihydrotestosterone concentration of beagle prostatic tissue: effect of age and hyperplasia.
Ewing LL; Berry SJ; Higginbottom EG
Endocrinology; 1983 Dec; 113(6):2004-9. PubMed ID: 6196180
[TBL] [Abstract][Full Text] [Related]
19. Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate.
Isaacs JT; Brendler CB; Walsh PC
J Clin Endocrinol Metab; 1983 Jan; 56(1):139-46. PubMed ID: 6183287
[TBL] [Abstract][Full Text] [Related]
20. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
Anderson RA; Wallace AM; Wu FC
J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
